A double-blind, placebo-controlled, crossover study of oral Vigabatrin (2-3 g/d) as add-on therapy for 31 patients with drug-resistant seizures is reported from the Neurological Clinic, Univ of Bologna School of Med, Italy.

Millichap, J.G., 0AD. Vigabatrin in Drug-Resistant Epilepsy. Pediatric Neurology Briefs, {volume}({issue}), p.{page}.DOI: https://doi.org/10.15844/pedneurbriefs-1-5-4

Millichap, J G. “Vigabatrin in Drug-Resistant Epilepsy”. Pediatric Neurology Briefs, vol. {volume}, no. {issue}, 0AD, p. {page}.DOI: https://doi.org/10.15844/pedneurbriefs-1-5-4

Millichap, J. G. (0AD). Vigabatrin in Drug-Resistant Epilepsy. Pediatric Neurology Briefs, {volume}({issue}), {page}.DOI: https://doi.org/10.15844/pedneurbriefs-1-5-4

Millichap, J Gordon. 0AD. “Vigabatrin in Drug-resistant Epilepsy”. Pediatric Neurology Briefs {volume} ({issue}): {page}.DOI: https://doi.org/10.15844/pedneurbriefs-1-5-4

1. Millichap JG. Vigabatrin in Drug-Resistant Epilepsy. Pediatric Neurology Briefs. 0AD;{volume}({issue}):{page}. DOI: https://doi.org/10.15844/pedneurbriefs-1-5-4

1. Millichap JG. Vigabatrin in Drug-Resistant Epilepsy. Pediatric Neurology Briefs. 0AD;{volume}({issue}):{page}.DOI: https://doi.org/10.15844/pedneurbriefs-1-5-4

Millichap JG, ‘Vigabatrin in Drug-resistant Epilepsy’ (0AD) {volume} Pediatric Neurology Briefs {page}DOI: https://doi.org/10.15844/pedneurbriefs-1-5-4

[1]J. G. Millichap, “Vigabatrin in Drug-Resistant Epilepsy”, Pediatric Neurology Briefs, vol. {volume}, no. {issue}, p. {page}, 0AD.DOI: https://doi.org/10.15844/pedneurbriefs-1-5-4

This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 license (unless stated otherwise) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Seizure Disorders

Vigabatrin in Drug-Resistant Epilepsy

Authors:

Abstract

Keywords: